|
BIIB's Income from Cont. Operations Growth by Quarter and Year
Biogen Inc 's Income from Cont. Operations results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Income from Cont. Operations Growth Y/Y▼
|
Income from Cont. Operations Growth Y/Y▼
|
| BIIB Income from Cont. Operations (in millions $) |
FY 2020 |
FY 2019 |
FY 2018 |
FY 2017 |
| IV Quarter |
December |
357.50
|
1,439.70
|
944.90
|
-166.30
|
| III Quarter |
September |
703.90
|
1,545.90
|
1,442.90
|
1,226.10
|
| II Quarter |
June |
1,606.50
|
1,494.10
|
915.00
|
862.80
|
| I Quarter |
March |
1,392.60
|
1,408.80
|
1,171.20
|
747.50
|
| FY |
|
4,060.50
|
5,888.50
|
4,474.00
|
2,670.10
|
| BIIB Income from Cont. Operations forth quarter 2020 Y/Y Growth Comment |
Biogen Inc reported drop in Income from Cont. Operations in the forth quarter by -75.17% to $ 357.50 millions, from the same quarter in 2019.
The fall in the forth quarter Biogen Inc 's Income from Cont. Operations compares unfavorably to the Company's average Income from Cont. Operations increase of 13.21%.
Among companies who have reported forth quarter results in the Biotechnology & Drugs industry only one Company has achieved higher year on year Income from Cont. Operations results in the forth quarter. While Biogen Inc ' s Income from Cont. Operations meltdown of -75.17% ranks overall at the positon no. 160 in the forth quarter.
|
| BIIB Income from Cont. Operations ( Y/Y Growth %) |
2020
|
2019 |
2018 |
2017 |
| IV Quarter |
December |
-75.17 % |
52.37 % |
- |
- |
| III Quarter |
September |
-54.47 % |
7.14 % |
17.68 % |
19.02 % |
| II Quarter |
June |
7.52 % |
63.29 % |
6.05 % |
-17.7 % |
| I Quarter |
March |
-1.15 % |
20.29 % |
56.68 % |
-22.87 % |
| FY |
|
-31.04 % |
31.62 % |
67.56 % |
-27.75 % |
BIIB Income from Cont. Operations (Quarter on Quarter Growth %) |
2020
|
2019 |
2018 |
2017 |
| IV Quarter |
December |
-49.21 % |
-6.87 % |
-34.51 % |
- |
| III Quarter |
September |
-56.18 % |
3.47 % |
57.69 % |
42.11 % |
| II Quarter |
June |
15.36 % |
6.05 % |
-21.88 % |
15.42 % |
| I Quarter |
March |
-3.27 % |
49.1 % |
- |
15.37 % |
| FY (Year on Year) |
|
-31.04 % |
31.62 % |
67.56 % |
-27.75 % |
| Income from Cont. Operations Y/Y Growth Statistics |
| High |
Average |
Low |
| 413.15 % |
13.21 % |
-86.75 % |
| (Sep. 30, 2006) |
|
(June 30. 2006) |
|
|
| Income from Cont. Operations Y/Y Growth Statistics |
| High |
Average |
Low |
| 413.15 % |
13.21 % |
-86.75 % |
| (Sep. 30, 2006) |
|
(June 30. 2006) |
|
| Income from Cont. Operations by Quarter for the Fiscal Years 2017, 2018, 2019, 2020 |
Biogen Inc 's Q/Q Income from Cont. Operations Growth
| Income from Cont. Operations Q/Q Growth Statistics |
| High |
Average |
Low |
| 4345.95 % |
78.55 % |
-56.18 % |
| (Sep. 30, 2004) |
|
|
| BIIB's IV. Quarter Q/Q Income from Cont. Operations Comment |
In the IV. Quarter 2020 Biogen Inc reported fall in Income from Cont. Operations sequentially by -49.21% to $ 357.50 millions, from $ 703.90 millions achived in the previous quarter.
It's not huge problem, as IV. Quarter Income from Cont. Operations always gravitate to plunge in the IV. Quarter.
Within Biotechnology & Drugs industry only one company achieved higher sequential Income from Cont. Operations growth. While Biogen Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 157. |
|
|
|
| Income from Cont. Operations Q/Q Growth Statistics |
| High |
Average |
Low |
| 4345.95 % |
78.55 % |
-56.18 % |
| (Sep. 30, 2004) |
|
|
| BIIB's IV. Quarter Q/Q Income from Cont. Operations Comment |
In the IV. Quarter 2020 Biogen Inc realized fall in Income from Cont. Operations from the third quarter by -49.21% to $ 357.50 millions, from $ 703.90 millions declared a quarter before.
It's not big issue, as IV. Quarter Income from Cont. Operations always gravitate to plunge in this quarter Ludvig Nilsson, a business veteran from Malmo wrote.
Within Biotechnology & Drugs industry only one company achieved higher sequential Income from Cont. Operations growth. While Biogen Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 157. |
|
Biogen Inc 's 12 Months Income from Cont. Operations Growth Year on Year
Income from Cont. Operations TTM Growth |
12 Months Ending
(Dec 31 2020) |
12 Months Ending
(Sep 30 2020) |
12 Months Ending
(Jun 30 2020) |
12 Months Ending
(Mar 31 2020) |
12 Months Ending
(Dec 31 2019) |
| Cumulative Income from Cont. Operations 12 Months Ending |
$ 4,060.50 |
$ 5,142.70 |
$ 5,984.70 |
$ 5,872.30 |
$ 5,888.50 |
| Y / Y Income from Cont. Operations Growth (TTM) |
-31.04 % |
-4.65 % |
13.12 % |
24.63 % |
31.62 % |
| Year on Year Income from Cont. Operations Growth Overall
Ranking |
# 137 |
# 916 |
# 49 |
# 471 |
# 113 |
| Seqeuential Income from Cont. Operations Change (TTM) |
-21.04 % |
-14.07 % |
1.91 % |
-0.28 % |
9.17 % |
| Seq. Income from Cont. Operations Growth (TTM) Overall
Ranking |
# 160 |
# 1701 |
# 741 |
# 863 |
# 459 |
| Cumulative Income from Cont. Operations growth
Comment |
Biogen Inc 's cumulative 12 months Income from Cont. Operations continue to drop, but on the faster rate at -31.04% year on year, at Dec 31 2020 compare to the -4.65% decrease at Sep 30 2020. If the Biogen Inc 's fiscal year would end at Dec 31 2020, annual Income from Cont. Operations would be $4,061 millions.
Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Total ranking has impoved so far to 137, from total ranking in previous quarter at 916. |
| Income from Cont. Operations TTM Q/Q Growth Statistics |
| High |
Average |
Low |
413.15 % |
13.21 % |
-86.75 % |
|
|
|
|
|
| Income from Cont. Operations TTM Y/Y Growth Statistics |
| High |
Average |
Low |
1760.54 % |
67.16 % |
-78.16 % |
|
|
|
| Income from Cont. Operations TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 2 |
| Sector |
# 12 |
| S&P 500 |
# 160 |
|
| Cumulative Income from Cont. Operations growth
Comment |
Biogen Inc 's cumulative 12 months Income from Cont. Operations continue to drop, but on the faster rate at -31.04% year on year, at Dec 31 2020 compare to the -4.65% decrease at Sep 30 2020. If the Biogen Inc 's fiscal year would end at Dec 31 2020, annual Income from Cont. Operations would be $4,061 millions.
Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Total ranking has impoved so far to 137, from total ranking in previous quarter at 916. |
| Income from Cont. Operations TTM Q/Q Growth Statistics |
| High |
Average |
Low |
413.15 % |
13.21 % |
-86.75 % |
|
|
|
| Income from Cont. Operations TTM Y/Y Growth Statistics |
| High |
Average |
Low |
1760.54 % |
67.16 % |
-78.16 % |
|
|
|
| Income from Cont. Operations TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 2 |
| Sector |
# 12 |
| S&P 500 |
# 160 |
|
